Expert review of anticancer therapy | 27 Sep 2016
B Thapa, DN Watkins and T John
Initial data of immune based therapy showed promise for improving malignant mesothelioma (MM) treatment. However, the results of such treatments have neither been predictable nor consistent and recent clinical studies of immune checkpoint inhibitors in MM have dampened initial enthusiasm.
* Data courtesy of Altmetric.com